Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway

Abbas K. Samadi, PhD,Joseph Bazzill, BS,Xuan Zhang, PhD,Rob Gallagher, PhD,Hauping Zhang, PhD,Rao Gollapudi, PhD,Kelly Kindscher, PhD,Barbara Timmermann, PhD,Mark S. Cohen, MD, FACS

Background. Despite development of current targeted therapies for medullary thyroid cancer (MTC), long-term survival remains unchanged. Recently isolated novel withanolide compounds from Solanaceae physalis are highly potent against MTCs. We hypothesize that these withanolides uniquely inhibit RET phosphorylation and the mammalian target of rapamycin (mTOR) pathway in MTC cells as a mechanism of antiproliferation and apoptosis.

Methods. MTC cells were treated with novel withanolides and MTC-targeted drugs. In vitro studies assessed cell viability and proliferation (MTS; trypan blue assays), apoptosis (flow cytometry with Annexin V/PI staining; confirmed by Western blot analysis), long-term cytotoxic effects (clonogenic assay), and suppression of key regulatory proteins such as RET, Akt, and mTOR (by Western blot analysis).

Results. The novel withanolides potently reduced MTC cell viability (half maximal inhibitory concentration [IC50], 270–2,850 nmol/L; 250–1,380 nmol/L for vandetanib; 360–1,640 nmol/L for cabozantinib) with induction of apoptosis at <1,000 nmol/L of drug. Unique from other targeted therapies, withanolides suppressed RET and Akt phosphorylation and protein expression (in a concentration- and time-dependent manner) as well as mTOR activity and translational activity of 4E-BP1 and protein synthesis mediated by p70S6kinase activation at IC50 concentrations.

Conclusion. Novel withanolides from Physalis selectively and potently inhibit MTC cells in vitro. Unlike other MTC-targeted therapies, these compounds uniquely inhibit both RET kinase activity and the Akt/mTOR prosurvival pathway. Further translational studies are warranted to evaluate their clinical potential. (Surgery 2012;152:1238-47.)

Although the incidence of medullary thyroid cancer (MTC) has grown each year, recently >2,900 new cases reported in the United States in 2010,1 survival statistics in this disease have not significantly improved over the last 3 decades, warranting novel therapies with better efficacy. For early stage disease confined to the thyroid or locoregional nodes, 5-year disease-specific survival rates have been reported at >80%; however, once tumors metastasize systemically, survival drops significantly to <55%.2,3 Operative resection is the standard of care for local disease and recurrence; however, >50% of patients recur or progress despite optimal operative resection.2

Standard chemotherapy regimens have limited efficacy in poorly differentiated thyroid cancers such as MTC. Response rates are often temporary and occur in <10–20% of patients and are without long-term benefit. Additionally, these drugs carry systemic toxicities that can be dose limiting.4 Recently, targeted therapies developed on the genetic and molecular basis of MTCs have led to several
Phase I, II, and III human trials worldwide. Because a majority of MTCs are owing to mutations of the RET proto-oncogene (which encodes a transmembrane tyrosine kinase receptor), a number of tyrosine kinase inhibitors (TKI) and multikinase inhibitors have been developed in the last decade, including RET-kinase–specific inhibitors that share the property of binding to the RET/ATP-binding pocket. These TKIs that target RET include drugs such as vandetanib, sorafenib, sunitinib, imatinib, axitinib, motesanib, gefitinib, and cabozantinib (XL184). Although these drugs may stabilize disease progression in many patients, they lack durable, long-term responses and carry moderate systemic toxicity for many patients. Opportunities, therefore, remain to identify novel durable therapies for advanced MTC.

Natural products continue to play a highly significant role in the drug discovery and development process, particularly in the area of cancer therapeutics, where a majority of the most widely used cytotoxic agents are of natural origin. Several genera in the large plant family Solanaceae produce compounds called withanolides, of which the most important and well-described is the steroidal lactone, withaferin A (WA). The withanolides exert a number of different effects including anti-stress, anti-inflammatory, and cytotoxic activities; however, their role as anticancer agents in MTC is currently being investigated.

WA isolated from the Withania somnifera plant has been shown to significantly inhibit MTC tumor mass in vivo in a metastatic mouse model. In addition to induction of apoptosis and inhibition of the PI3kinase/Akt pathway by WA in thyroid cancers, WA has also been reported to inhibit Notch signaling and the mammalian target of rapamycin (mTOR) pathway in colon cancer cells. In the present study, the anti-cancer activity of several novel withanolides will be examined in MTC cells and compared with WA and TKIs used in MTC clinical trials such as 17-AAG, axitinib, vandetanib, and cabozantinib. We hypothesize that novel withanolide derivatives, unlike other targeted kinase inhibitors, uniquely inhibit MTC cell proliferation and induce apoptosis through a combination of RET kinase inhibition as well as inhibition of the Akt/mTOR signaling pathway.

MATERIALS AND METHODS

Reagents and cell culture. All chemical reagents were obtained from Sigma Chemical Co (St. Louis, MO) unless specified otherwise. Antibodies to phospho-Thr-389 S6K, phospho-Thr-36/47 4E-BP1, phospho-Ser-65 4E-BP1, phospho-mTOR, mTOR, phospho-Akt, Akt, phospho-ERK, ERK, phospho-p70S6K, p70S6K, caspase 3, and PARP from Cell Signaling Technology (Beverly, MA); antibodies to actin from Millipore (Temecula, CA), and horseradish peroxidase-labeled anti-mouse, anti-goat, and anti-rabbit secondary antibodies from Santa Cruz Biotechnology (Santa Cruz, CA). The human MTC cell lines included MTC-TT cells (derived from MEN2A patient with codon 634 mutation) obtained from ATCC (Manassas, VA) and DRO 81-1 cells (derived from a patient with sporadic MTC) were provided by Dr Guy Juillard (University of California, Los Angeles, CA). The papillary thyroid cancer cell-line, TPC 1 (with a RET/PTC mutation), was obtained from SelleckChem (Houston, TX). Additional drugs included several TKIs used in MTC trials. Axitinib (Cat # A-1107), vandetanib (Cat # V-9402), and 17-AAG (Cat # A-6880) were obtained from LC Laboratories (Woburn, MA); cabozantinib (XL184) (Cat # S1119) was obtained from Dr Barbara Timmermann’s laboratory (Lawrence, KS). Additional drugs included several TKIs used in MTC trials. Axitinib (Cat # A-1107), vandetanib (Cat # V-9402), and 17-AAG (Cat # A-6880) were obtained from LC Laboratories (Woburn, MA); cabozantinib (XL184) (Cat # S1119) was obtained from ATCC.

Cell growth assay. Cell viability was determined by dye-reduction assay (Promega, Madison, WI) measuring mitochondrial respiratory function according to the manufacturer’s instruction. MTC cells were plated in 96-well microtitre plates and treated with drugs at various concentrations.
concentrations (0.03–20 mmol/L) for 72 hours. Cells were then incubated with MTS dye (2 mg/mL per 20 µL/well) for 2 hours. Absorbance was determined in a Biotek plate reader at 490 nm. The absorbance is directly related to viable cell number.

**Flow cytometry analysis.** For cell cycle studies, DRO81-1 cells (10^5 cells) in 60-mm plates were exposed to withanolides for 24 and 48 hours. After cells were washed, DNA was stained with 50 µg/mL propidium iodide (PI) solution (0.02 µg/µL RNase A, 1.0 mg/mL sodium citrate-dihydrate, 0.1 µg/µL PI, 0.3% Triton X-100) at 25°C for 30 minutes. For fluorescence-activated cell sorting analysis, the FACScan (Becton Dickinson, Franklin Lakes, NJ) was used. Cell-cycle analysis was performed with the use of ModFit LT software (Verity Software House, Inc, Topsham, ME). For Annexin V/PI studies, cells were washed after treatment and were collected by trypsinization. Cells were washed twice with 1/3 phosphate-buffered saline (PBS) and then stained with Annexin V-FITC and PI according to the manufacturer’s instruction (BD Bioscience, San Jose, CA).

**Western blot analysis.** After treatment, DRO81-1 cells were lysed with ice-cold lysis buffer [150 mmol/L NaCl, 40 mmol/L HEPES (pH 7.4), 2 mmol/L EGTA, 2.5 mmol/L MgCl₂, 1% Triton X-100, and 1X EDTA-free protease inhibitors (Sigma)]. The soluble fractions from cell lysates were isolated by centrifugation at 14,000 rpm for 20 minutes in a microfuge. Protein concentration was determined by bichinchoninic acid protein assay kit according to the manufacturer’s instructions (Pierce Biotechnology, Rockford, IL). Equivalent protein extracts (15–50 mg) from each sample were electrophoresed on 8–15% sodium dodecyl sulfate polyacrylamide gel electrophoresis mini gels. Proteins were transferred onto Hybond nitrocellulose (Amersham, Piscataway, NJ) in a Bio-Rad Trans blot apparatus. Nitrocellulose matrices were preblocked with 3% nonfat milk powder in PBS and 0.05% Tween-20 for 1 hour at room temperature. After PBS–Tween washes, preblocked matrices were incubated with appropriate dilution of primary antibody. Reactive bands were visualized specific bands by enhanced chemiluminescence ECL (Pierce Biotechnology).

**Clonogenic assay.** DRO81-1 cells were cultured into 60-mm plates (300 cells/plate), then left in

---

**Table. IC₅₀ levels of novel withanolides and tyrosine kinase inhibitors**

<table>
<thead>
<tr>
<th>Compounds</th>
<th>DRO81-1</th>
<th>MTC-TT</th>
<th>TPC-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>WA</td>
<td>1.09</td>
<td>2.76</td>
<td>0.48</td>
</tr>
<tr>
<td>WGA</td>
<td>2.85</td>
<td>2.17</td>
<td>0.29</td>
</tr>
<tr>
<td>WGD</td>
<td>5.84</td>
<td>17.0</td>
<td>4.39</td>
</tr>
<tr>
<td>WGB-MA</td>
<td>0.96</td>
<td>1.31</td>
<td>0.077</td>
</tr>
<tr>
<td>WGB-DA</td>
<td>0.58</td>
<td>0.86</td>
<td>0.030</td>
</tr>
<tr>
<td>WGA-TA</td>
<td>0.27</td>
<td>1.03</td>
<td>0.039</td>
</tr>
<tr>
<td>Axitinib</td>
<td>1.18</td>
<td>0.78</td>
<td>0.95</td>
</tr>
<tr>
<td>Vandetanib</td>
<td>2.38</td>
<td>0.25</td>
<td>0.27</td>
</tr>
<tr>
<td>XL184</td>
<td>2.64</td>
<td>0.36</td>
<td>0.16</td>
</tr>
<tr>
<td>17-AAG</td>
<td>0.012</td>
<td>0.024</td>
<td>0.015</td>
</tr>
</tbody>
</table>

Fig 1. Comparative chemical structures of withanolides and tyrosine kinase inhibitors tested. Chemical structures are included for WA, WGA, WGA-TA, WGD, WGB-MA, WGB-DA, axitinib, vandetanib, caboazantinib, and 17-AAG.
the incubator overnight to attach. Cells were treated with withanolides for 72 hours at 37 °C in a humidified atmosphere of 95% air and 5% CO₂. After treatment media was removed and fresh media without drug was added. Cells incubated for 2 weeks to allow the formation of macroscopic colonies. Media was changed 3 times a week. The cells were then stained with Coomassie blue. At least 2 independent experiments, each using triplicate plates, were performed for each cell line. Photographic documentation was recorded.

Statistical analysis. All in vitro data points were run in triplicate and expressed as a mean values ± standard error of the mean. Raw data were analyzed by a Student’s unpaired t-test and Fisher exact tests using a standard statistical analysis software package (SPSS version 17.0; SPSS Inc, Chicago, IL); P < .05 was defined as significant.

RESULTS

Withanolides impair MTC cell growth in part through induction of apoptosis. DRO81-1, TT-cells, and TPC1 cells were incubated with each of the drugs structurally listed in Figure 1 for 72 hours (0.03–20 mmol/L) and cell viability was determined using MTS dye reduction assay. Half maximal inhibitory concentration (IC₅₀) values were determined for each compound in all 3 cell-lines tested and are tabulated in the Table. Of all the compounds tested, 17-AAG was the most potent in all cell-lines with an average IC₅₀ in MTC 18 ± 4 nmol/L. All of the withanolides tested demonstrated significant potency against MTC cells except for WGD, which structurally lacks the double bond in the A-ring of the molecule and results in a loss of anticancer activity (structure–activity–relationship; data not shown). The remaining withanolides demonstrated excellent potency in DRO81-1 MTC cells compared with the targeted TKIs, but were less potent than vandetanib and cabozantinib in TT cells. Addition of acetyl groups to the withalongolide A (WGA) molecule as noted with withalongolide B 4-acetate (WGB-MA; a mono-acetyl analog), withalongolide B 4,19-diacetate (WGB-DA, a di-acetyl analog) and withalongolide A 4,19,27-triacetate (WGA-TA, a tri-acetyl

Fig 2. Novel withanolides induce G2/M cell-cycle arrest in MTC cells. A, PI staining by flow cytometry of DRO81-1 cells exposed to WGA cells at concentrations of 1–6 μmol/L for 24 and 48 hours. Of note there is a significant shift in cell-cycle arrest with an increase in the size of the G2/M peak with increasing dose of WGA treatment at 48 hours. B, Bar graphs with quantitative shifts in the cell cycle of DRO81-1 cells treated with either WGA, WGB-MA, or WGB-DA for 24 or 48 hours. The shift was significant to G2/M arrest with withanolide treatment. (Color version of figure is available online.)
analog), resulted in increased potency compared with the parent molecule WGA. This was observed in all 3 cell-lines. Comparing the tri-acetyl and mono-acetyl analogs, WGA-TA was significantly more potent than WGB-MA in each cell line tested ($P < .01$). From this initial cell viability analysis, a ranking of potency for the withanolides from least potent to most potent would include WGD, WGA, WA, WGB-MA, WGB-DA, and WGA-TA. Owing to its stability and consistency of growth in vitro compared with TT cells, further mechanistic studies were carried out using DRO81-1 cells.

**Withanolides promote cell cycle arrest in MTC cells.** We next examined that the effect of novel withanolides on modulation of cell cycle progression in MTC cells. WGA induced a shift in cell cycle arrest from G0/G1 arrest to G2/M arrest in DRO81-1 cells at 6.0 μmol/L for 24 hours and both at 3.0 and 6.0 μmol/L for 48 hours treatment as noted by PI staining peaks on flow cytometry (Fig 2, A). This shift with treatment to G2/M arrest was also observed with WGB-MA and graphed quantitatively in Figure 2, B. After 48 hours WGA treatment at 3 μmol/L there was a shift in G2/M arrest from 20% to 35% of cells arrested at this checkpoint, whereas at 6 μmol/L this shift increased to 40% of cells in G2/M ($P < .01$ compared with controls). Similarly, at 48 hours both 1 and 3 μmol/L WGB-MA resulted in an increase in G2/M arrest from 25% to 42% of cells arrested at this checkpoint ($P < .01$). WGB-DA also induced G2/M cell-cycle arrest in MTC cells. After 24 hours of treatment, WGB-DA treatment induced G2/M shift from 23% to 50% and 40% at 1 and 3 μmol/L. Similar
results were obtained with MTC cells were treated with WGB-DA for 48 hours (Fig 2, B).

**Withanolides induced apoptosis in MTC cells.** To explore the mechanism of withanolide-induced growth suppression, we examined the effect of these novel compounds on the induction of apoptosis in MTC cells. Initial evaluation was performed with annexin V/PI staining on flow cytometry and confirmed with caspase 3 activation and poly-ADP ribose polymerase (PARP) cleavage on Western blot analysis. WGA induced apoptosis in MTC cells at 3 and 6 μmol/L for 24 hours (5.1% and 12.0%, respectively) and 48 hours (12.2% and 49%, respectively; P < .001; Fig 3, A and D). Similarly WGB-MA induced apoptosis at 1 and 3 μmol/L in MTC cells at 24 hours (3% and 22%, respectively) and at 48 hours (28% and 82%, respectively; P < .001; Fig 3, B and D). WGB-DA was the most potent withanolide for inducing apoptosis in MTC cells. At 1 and 3 μmol/L WGB-DA in MTC cells at 24 hours gated 11% and 46% of cells toward apoptotic cell death, respectively, and at 48 hours this increased to 68% of cells undergoing apoptosis at 1 μmol/L and 83% of cells undergoing apoptosis at 3 μmol/L (P < .001; Fig 3, C and D). To confirm these results the levels of cleaved caspase 3 and the endogenous caspase 3 substrate, PARP, were determined by Western blot analysis of cells treated for 24 hours. Fig 3, E shows that WGB induced cleavage of caspase at 6 μmol/L concentration after 24 hours treatment, whereas the more potent withanolides WGB-MA and WGB-DA activated caspase 3 and cleaved PARP starting at 1 μmol/L drug levels and peaking around 3 μmol/L of drug. Similarly, the effect of axitinib, vandetanib- and XL184-treated DRO81-1 cells demonstrated that these TKIs slightly induced caspase activation and PARP cleavage but this occurred less robustly than observed with the novel withanolide compounds (Fig 3, E).

**Withanolides promote inhibition of clonogenic growth.** Clonogenic assay was performed to determine the long-term toxicity effect of withanolides on MTC cells. Pulse-exposure of DRO81-1 cells for 3 days to either 1 μmol/L WGA, 250 nmol/L WGB-MA, or 250 nmol/L WGB-DA irreversibly inhibited 80% clonogenic growth compared with untreated DRO81-1 cells (Fig 4).

**Withanolides suppressed activation of RET and Akt/mTOR pathway.** To elucidate the mechanism by which withanolides induce apoptosis and suppress MTC cell viability and growth, we evaluated by Western blot analysis the effects of these drugs on several key regulatory pathways and proteins in MTC cells, specifically activation of RET, the MAP kinase pathway (ERK1/2) and the Akt/mTOR pathway. Because alterations in protein expression in response to drug treatment may be both time- and concentration-dependent, we evaluated each drug at multiple doses (above and below IC50 levels) at 12 hours and at 24 hours treatment. Comparisons of expressions of these signaling proteins are shown for each withanolide drug in Fig 5. WGA, WGB-MA, and WGB-DA each demonstrated a consistent pattern related to their mechanistic effects on MTC signaling pathways. Each of these withanolides downregulated total and phospho-RET expression levels as well as total and phospho-mTOR expression levels and total and phospho-Akt levels. Downstream mTOR signaling was also affected in these withanolide-treated cells. Because mTOR modulates activity of downstream 4E-BP1 and p70S6kinase to regulate RNA translation and protein synthesis respectively, these proteins were evaluated in response to drug treatment. All 3 withanolides demonstrated inhibition of 4E-BP1, phospho-4E-BP1, p70S6kinase, and
phospho-p70S6Kinase at 24 hours drug treatment with downregulation occurring at 500 nmol/L concentrations, which is at or below IC_{50} drug levels in DRO81-1 cells (Fig 5). ERK1/2 expression levels, however, were increased with drug treatment. Inhibition of both RET activity and the Akt/mTOR pathway occurred as early as 12 hours after treatment. WGD, which has the lowest potency in vitro and lacks the double bond in the A-ring (which conveys activity), demonstrated upregulation of RET, Akt, ERK1/2, and the mTOR pathway, including 4E-BP1 and p70S6 kinase, which coincided with its lack of in vitro growth inhibition or induction of apoptosis (Fig 5, D). Finally, vandetanib and cabozantinib (clinical TKIs used in MTC) were evaluated for their effects on the same regulatory proteins in MTC cells (Fig 6). Both of these drugs inhibited phospho- and total RET expression levels at 24 hours, although significantly less robustly than noted with WGB-MA or WGB-DA withanolide treatment (P < .01 based on densiometry measurements of comparative protein bands). Interestingly, these targeted therapies did not inhibit mTOR, or its downstream constituent p-70S6 kinase, although only at 3 μmol/L (10 times the IC_{50} level) did
vandetanib slightly downregulate 4E-BP1 levels. Both TKIs markedly downregulated ERK1/2 and phospho-ERK expression levels while upregulating Akt expression levels in a dose-dependent manner.

**DISCUSSION**

For patients with unresectable or advanced MTC, a targeted therapy trial has been an approach of choice when such treatments are available. With cabozantinib completing its Phase III international trial and vandetanib’s recent US Food and Drug Administration approval for use in MTC, these targeted agents are the most commonly used clinically.\(^{17}\) Outcomes from these studies, however, are modest at best and each of these drugs carry moderate toxicity profiles.

Natural products have played a significant role in the discovery and development of new anticancer agents, and represent a rich source of biologically active compounds. More than 80% of anticancer drugs introduced from January 1981 to October 2008 were natural products, semi-synthetic analogs, or synthetic compounds based on natural product pharmacophores.\(^{18}\) Withanolides are naturally occurring C-28-steroidal lactones built on an intact or rearranged ergostane scaffold in which C-22 and C-26 are appropriately oxidized to form a \(\delta\)-lactone ring on the 9-carbon side chain.\(^{19}\) These compounds possess various biological activities in vitro and in vivo, including antimicrobial, radiosensitizing, antineoplastic, and cytotoxic effects.\(^{20-22}\) Although recent studies have demonstrated that WA suppresses the growth of human cancer cell lines in vitro and in vivo by causing apoptosis,\(^{15}\) the precise mechanism, including the signals and the pathways by which WA induces cell death, is not fully understood. Our group has demonstrated that WA inhibits MTC growth in vivo suppressing RET phosphorylation in the tumors as well as inhibiting calcitonin secretion.\(^{15}\) This compound did not result in weight loss or any clinical toxicity in vivo and has good oral bioavailability.

In the current experiments, we demonstrated that 3 novel withanolide compounds from the Physalis plant demonstrated potent activity against MTC cells in vitro with IC\(_{50}\) levels for acetylated analogs WGB-MA and WGB-DA in the mid-nanomolar range, comparable with the potency of targeted TKIs such as vandetanib and cabozantinib. Treatment of MTC with withanolides significantly irreversibly reduced clonogenic formation. Their mechanism of action for this antiproliferative effect involves several processes including induction of apoptosis, which was significantly enhanced with the acetylated analogs WGB-MA and WGB-DA and involved >60% of cells at 1 \(\mu\)mol/L WGB-DA and 83% of cells at 3 \(\mu\)mol/L of drug. These compounds also affect cell-cycle arrest, with significant shift of cells into G2/M arrest, as reported with WA.\(^{21}\)

Given the high apoptotic rate with treatment, we investigated several key regulatory proteins in MTC cells. The RET proto-oncogene is activated in
MTC, leading to activation of the RAS/RAF/MEK/ERK signaling pathway. Mutant RET with representative MEN2A mutation at Cys-634 (RET-MEN2A) has been shown to activate PI3 kinase/Akt pathway. Furthermore, a recent study by Kouvaraki et al demonstrated that mTOR is highly active in MTC cells. Because mTOR signaling controls protein synthesis through regulation of translation initiation, identifying small molecules that target the mTOR pathway represents a promising target for investigational therapy in MTC patients. The present study shows that novel withanolides WGA, WGB-MA, and WGB-DA reduce both RET and Akt/mTOR activation in MTC cells with inhibition of mTOR RNA translation through knockdown of 4E-BP1. This mechanism is unique from TKIs like vandetanib or cabozantinib, which knock down RET and the MAP kinase pathway but do not affect the mTOR pathway. These TKIs upregulate Akt expression levels, which may explain in part why apoptosis is not seen as robustly in MTC cells with these therapies. These experiments are the first to identify this unique mechanism of action of withanolide compounds in MTC cells. Because the novel withanolide molecules WGA, WGB-MA, and WGB-DA work on different key regulatory pathways than TKIs in MTC cells, there may be a role for synergy or combination therapies of withanolides with these targeted TKIs. With similar mechanism to their parent molecule, WA, these novel natural withanolide analogs have potent anticancer activity in vitro, whereas WA itself has now progressed into a phase I clinical trial in India in patients with advanced osteosarcomas. Over-all, these novel withanolides demonstrate excellent potency and anticancer activity in MTCs in vitro downregulating both RET and mTOR activity. Ongoing in vivo efficacy and toxicity studies will better evaluate their clinical potential.

REFERENCES

DISCUSSION

Dr Herb Chen (Madison, WI): It looks like your compounds are pretty effective for medullary thyroid cancer. Have you looked at other types of neuroendocrine tumors?

Dr Mark S. Cohen (Kansas City, KS): We haven’t looked at neuroendocrine tumors as of yet. I’ve looked at other types of cancer, like melanoma and breast cancer, and they are fairly active in those. We have not looked at carcinoid or adrenal cancers, so those are other opportunities that we plan to explore.

Dr Marybeth Hughes (Bethesda, MD): My question for you—and this is just my ignorance—what are the available phase I data for these compounds? You showed that you can get major apoptosis with low concentrations. Are those achievable in serum, PKs, all that?

Dr Mark S. Cohen: Interestingly, there’s has been a phase I trial with withaferin A in India. And based on early data from that trial, the pharmacokinetics demonstrated that the levels of withaferin A, which was obtained from giving the *Ashwagandha* plant, were not detectable in the serum.

We’ve completed early pharmacokinetics with the fruit of the *Physalis* plant, looking at these withanolide derivatives. Giving mice just the whole fruit as a gavage, we could achieve low nanomolar concentrations in the mice in the serum, which is not far from the IC<sub>50</sub> level. We believe, therefore, that these compounds actually get metabolized into withaferin A and that these derivatives may be acting as a withaferin A prodrug. We are in the process of increasing their potencies to a point where these compounds could achieve therapeutic serum levels.

Dr Jennifer Rosen (Boston, MA): Some people here know I have an interest in complementary and alternative medicine use in thyroid cancer patients. And I’m very happy to see that this is being done in a scientific fashion. Can you comment on the preparation, how it’s used, how you actually extract it, and do you know what the active ingredient in it is, the measurability of it?

Dr Mark S. Cohen: Our medicinal chemists actually perform the multistep extraction process. You can eat the whole fruit from the plant and colloquially it has been referred to as the tomatillo. When they perform the extractions from the whole plant, these withanolides are pulled down and purified from those extracts, resulting in several unique withanolide compounds that were isolated. The most prevalent of these compounds is the withanolide A, which actually converts to withaferin in the body once it’s metabolized. So that’s the main compound in the plant from this group of withanolides.

Dr Jennifer Rosen: Is there a way to measure the activity so you could, say, dose patients accordingly?

Dr Mark S. Cohen: We are doing those studies right now, actually, to look at either using the whole fruit or the purified withanolide compound. We currently have murine pharmacokinetics completed and plan to repeat this in canines before translating this to a phase I clinical trial.

Dr Wen Shen (San Francisco, CA): I think this is a great opportunity that we should put out a thyroid cancer cookbook, in all seriousness, because of all the different edible compounds that we’ve discussed, the turmeric, red wine, green tea, et cetera, combine it with the ficus, low-iodine cookbook. I think someone should take this on, and it will be kind of an exciting product for our patients.

Dr Mark S. Cohen: I would agree with that. It sounds like a recipe for thyroid health and possibly even prevention of recurrence.